DIMT1

Across TCGA pan-cancer cohorts, DIMT1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DIMT1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DIMT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DIMT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where DIMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.675	0.326	.012	29	view →
HNSC	OS	Median	IV	0.134	1.000	.008	18	view →
CCRCC	OS	Median	III,IV	0.133	0.989	.013	15	view →
LSCC	DFS	Tertile	II,III,IV	0.972	0.731	.006	12	view →
LUAD	DFS	Quartile	All	0.739	0.426	.008	11	view →
GBM	OS	Median	All	0.448	0.304	.031	3	view →
UCEC	DFS	Tertile	All	1.000	0.915	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DIMT1–PDAC (DFS)

Open the PDAC breakdown →